SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule disrupting agents

Sharon Amir, Nicola J. Mabjeesh

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

SEPT9 is a mammalian septin family member. There is growing evidence that SEPT9 plays a role in cancer. The protein product, SEPT9_V1, associates with microtubules and interacts with hypoxia-inducible factor (HIF)-1α, the regulated subunit of the key transcription factor HIF-1. HIF-1 transcriptional activity is thoroughly dependent on intact microtubules. We tested the hypothesis that SEPT9_V1 confers resistance to microtubule-mediated HIF-1 inhibitors. SEPT9_V1 protein expression was strongly correlated with susceptibility of a wide range of cancer cells to 2-methoxyestradiol and paclitaxel. Our results revealed that SEPT9_V1 could serve as a biomarker for therapeutic resistance to microtubule disrupting agents.

Original languageEnglish
Pages (from-to)1926-1931
Number of pages6
JournalCancer Biology and Therapy
Volume6
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Funding

FundersFunder number
Bat Sheva De Rothschild Foundation
Israel Academy of Science
M.K. Humanitarian Foundation
PCF Israel
Ministry of Health, State of Israel

    Keywords

    • 2-methoxyestradiol
    • Cancer
    • HIF
    • Microtubules
    • Paclitaxel
    • SEPT9
    • Septins

    Fingerprint

    Dive into the research topics of 'SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule disrupting agents'. Together they form a unique fingerprint.

    Cite this